Many attempts (some successful) have been made in the past to obtain tumour-specific antibodies by immunizing animals with tumour cells or extracts followed by removal by absorption of antibodies reactive with the corresponding normal cells. However, the amount of residual specific antibody represented a minute proportion of the remaining Ig and other proteins present in an antiserum.
Specificity of labelling was difficult to achieve, and the preparations were liable to be highly immunogenic.
Monoclonal antibodies have changed all this. A large proportion of the Ig secreting cells in a sample from an immunized mouse or rat can be fused with myeloma cells selected to possess very active potential Ig-secretion machinery but by themselves secreting little or no Ig of their own. If a reasonably simple screening method is available, it is possible to select hybridoma secreting antibodies with a desired specificity, even if these occurred only rarely in the starting population. It is becoming possible to predict which determinants on a complex antigen will be most immunogenic, and to design antigens so as to elicit antibodies against attached chosen structural determinants (when these are known).
Although it is not possible to predict in advance what will be the Ig subclass or the affinity for the selected antigen of any particular hybridoma, with persistence and some luck hybridomas secreting Ig of the desired subclass and affinity can be obtained.
The essential feature of monoclonal antibodies is their goodness of fli with the shape of quite small tertiary structures exposed at the surface of the antigen. This Radioimmunodetection is the method of cancer diagnosis using radiolabelled tumour associated polyclonal or monoclonal antibodies. The standard radionuclide used to date has been 1-131. 111In and have recently been introduced but as yet have undesirable RES accretion. Studies at our centre with conventional goat and murine monoclonal antibodies against carcinoembryonic antigen (CEA), alpha-foetoprotein (AFP), human chorionic gonadotrophin (HCG), prostatic acid phosphatase (PAP), colon-specific antigen-p (CSAp) and Reisfeld's high mol. wt melanoma antigen (9.2.27) have a sensitivity of 90%. In 11 out of 51 patients with colorectal cancer, occult cancer was detected and was later confirmed by other methods, achieving a lead time of up to 40 weeks. Radioimmunodetection revealed all tumours whilst CAT and NMR scanning disclosed 37.5% and 50% respectively. Image resolution ranged between 1.5-2.0 cm tumours. In pancreatic cancers, single photon emission tomography improved imaging.
1311 anti-CEA IgG was able to retard tumour growth of GW-39 human colonic carcinoma xenografts in animals. Therefore, a clinical Phase I/II trial of radioimmunotherapy has begun. Patients will receive between 25-75 mCi 1311 labelled anti-CEA or anti-AFP antibodies weekly for 4 weeks.
Current results indicate a blood T-of 24-36 h and the formation of circulating immune complexes.
Antibody guided irradiation of cancer S.E. Order
Department of Radiation Oncology, The Johns Hopkins Oncology Centre, Baltimore, MD, USA Radiolabelled 1311 antiferritin will selectively target tumours that synthesise and secrete ferritin, hepatoma, Hodgkin's disease, etc. In an H42E rat hepatoma, the 'biologic window' that allows selective targeting without normal tissue uptake has directly correlated with neovasculature and ferritin synthesis. In dose escalation studies in hepatoma tumour saturation was determined by volumetric calculations (mean vol. 1000-1500ml) and radioactive concentration counts (6-12 pCimg-1) and has shown that 30 mCi (10 mCi mg-1 IgG) saturated the tumour. The 4 day tumour effective half life led to a second dose of 2OmCi and achieved a 10-12 Gy tumour dose. The toxicity was thrombocytopenia. Volumetric reconstruction of serial CAT scans allowed quantitation of tumour volumes for evaluation of remission. Administration of antiferritin from different species was associated with different tumour effective half lives (rabbit, pig, monkey, bovine 3-4 days) (goat, sheep 2 days), and avoided anti-antibody reactions. In a 105 hepatoma patient experience 48% of the patients had at least partial remission, and 4% of these patients complete remission. One patient remains disease-free in complete remission, 3 years and 3 months, and another patient in partial remission, 5 years and 5 months. Fifteen percent of remitted patients are beyond 2 years.
In Hodgkin's disease, in MOPP-ABVD failures, 1311 antiferritin has a 40% partial remission rate and a 70% remission of B symptoms. Thrombocytopenia occurred earlier due to limited marrow reserve. Monoclonal antibodies to molecules on the cell surface membrane of human leucocytes have provided much information on developmental and functional subsets of haemopoietic cells, as well as on the function of the molecules themselves. For example, for T lymphocytes the identification of the cell surface molecules TI, T3, T4, T6, T8, and Ti1 has made it possible to study intra-thymic T cell ontogeny, to identify functionally mature subpopulations of recirculating peripheral T lymphocytes and to study some of the molecular events involved in T cell activation. Clinically, monoclonal antibodies to leucocytes have been useful both in assessing immune status and in analysing haemopoietic malignancies. Normal haemopoietic differentiation depends upon an interaction between the progenitor cells and their microenvironment. We have recently raised monoclonal antibodies to molecules in/on the epithelial component of the human thymus microenvironment, and using these can identify several cell surface and secretory products that may be responsible for progenitor/lymphocyte positioning, migration and differentiation within the thymus. We are currently using these reagents to analyse the thymic microenvironment in myasthenia gravis. Preliminary data indicate that whereas in patients with thymic hyperplasia it is the subcapsular/medullary epithelium that is proliferating, in thymoma cases it is the cortical epithelium that is involved in the neoplasia. In the haemopoietic system, the study of normal differentiation has greatly aided in the management of many leukaemias. In an attempt to apply a similar approach to the study of breast carcinomas, the differentiation of mammary epithelial cells is being investigated. To facilitate this study, monoclonal antibodies have been produced to (1) human B casein, a milk protein which is a unique product of terminally differentiated breast epithelium, (2) cytokeratins, which are expressed exclusively by epithelial cells, the profile of expression being characteristic of a specific epithelial cell type, and (3) a large mol. wt mucin-like component present in human milk fat globule which is recognised by monoclonal antibodies HMFG-1 and 2. The HMFG-1 antigen is highly represented on this mucin and on lactating breast, and its presence has been associated with the decrease growth potential of normal breast epithelium in vitro. In contrast, the HMFG-2 antigen is poorly represented on the mucin, but is strongly expressed by most breast cancer cell lines and ductal carcinomas and its presence in the serum of advanced breast cancer patients may be associated with a bad prognosis.
These antibodies are now being used to characterise breast epithelial cells in vitro cultured on plastic and in collagen gels. Additionally, the HMFG-1 and 2 antibodies have been found to have practical uses in the clinic including (1) Amplification is achieved by causing the enzyme to be determined to produce a catalytic activator for a secondary enzyme system, the activity of which is measured. Thus the catalytic effect of the enzyme to be determined is multiplied by the catalytic effect of the activator it produces. The measured activity is correspondingly large.
The Six monoclonal antibodies (MAbs) were iodinated using chloramine T, IODO-GEN or N-bromosuccinimide to achieve increasing levels of iodine substitution. Immunoreactivity was characterised by sequential absorption, by Lineweaver-Burk-type extrapolation to binding at infinite antigen (melanoma cell) concentration, and by Scatchard plots. Our findings can be summarised as follows: (1) Immunoreactivity depended on iodine substitution ratios rather than on the iodination method, provided that mild reaction conditions were adopted.
(2) MAbs displayed considerable individuality with respect to the level of substitution they tolerated. (3) Iodination was found to be an all or none effect reducing the proportion of antibody molecules binding at antigen excess, or a gradual effect reducing binding affinity. Reduced immunoreactivity was clearly reflected by a poor performance of labelled MAbs in vivo, e.g. in immunoscintigraphy.
lodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method 25 mCi mg-' with immunoreactivities of 82+2% using 1251 and 66+5% using 1311. As the radioiodination is done in one sealed vial and takes <O min, this procedure is safe and can be performed in any nuclear medicine laboratory. The final product, which is sterile and pyrogen-free, is suitable for diagnostic and radiotherapeutic applications. We anticipate that this method has great implications for the use of iodinated antibodies for imaging and therapy making radioimmunodetection and antibody guided radiation therapy less restricted to specialised centres. Gadolinium-DTPA MoAb 19.9 are presently being investigated for their potential use as tumourspecific (NMR) imaging agents.
The strongly paramagnetic gadolinium complex reduces hydrogen proton relaxation. The metal ion (Gd3+) needs to be chelated with a suitable ligand (DTPA) to decrease the toxicity, and to enable coupling with MoAb 19.9 which is direct against specific tissues (human colon adenocarcinoma SW 1116, HT 29, and HRT 18 The monoclonal antibody is a homogeneous gamma globulin with many tyrosine radicals suitable for iodination using the gentle techniques refined for radioimmunoassay over many years. 1311 is unsuitable as the iodine label because its beta emission and long half-life cause high patient radiation when given in a dose sufficient to give good imaging sensitivity and its use should be limited to therapy. 123I with no beta emission, 13 h halflife and 16MeV gamma ray energy is ideal for imaging with the gamma camera. It is becoming more widely available and per MCi is half the price of IIIIn, the alternative label. It has been shown that 123I labelled monoclonal antibodies preserve their immunoreactivity whereas chelation for I1IIn labelling may cause cross-linking of antibodies, leading to high liver uptake and reduced immunoreactivity. The kinetics of antibody uptake favour a high sensitivity, short-lived radionuclide which gives a good signal. Our original technique of subtracting an early image from a later one has been refined through kinetic analysis of serial images with probability mapping. On the assumption that tissue background is decreasing with time and tumour uptake is increasing with time, serial images may be compared pixel by pixel and the frequency distribution of activity plotted. Using a least squares technique the clusters of pixels showing significant positive or negative deviation with time may be identified and the areas of significant change, at, for example, the P< 0.001 plotted on a map as a contour over the original data. This objective approach is needed to define that an abdomen is really clear or not of recurrence. TIOI is a murine monoclonal antibody (MOAB), IgG2a directed against a pan T-cell antigen present in high concentration in CTCL. 1 1 1 In labelling (5 mCi, 1 mg) was performed by a modification of the Krejcarek method (Hybritech, Inc.): 1311 labelling (2 mCi, 1 mg) was performed via the chloramine T method. Six patients received 1 mg 111In TI01 and 3 patients received 1mg 1311 TIOI i.v. by a 2-h infusion. By 24h all patients receiving 11"In T101 showed uptake in involved nodes as well as previously unsuspected nodes. Nodes as small as 5 x 5 mm were visualised. Skin plaques (6 patients) were negative whereas erythroderma (1 patient) was positive on scan. In addition, prominent liver, spleen and bone marrow uptake was visualised and persisted on serial scans. 1311 TIOl showed minimal nodal concentration in 1 patient and none in the other 2 patients. Although early images showed prominent liver, spleen and to a lesser extent bone marrow uptake, serial images showed rapid clearance of 1311 from these organs.
One patient received both 1311 and 1"'In-labelled TIOI with no localisation in involved nodes with 1311 label but prominent areas of nodal uptake and skin (erythroderma) with "'1In TIOI (4 days later). Plasma clearance was rapid for all preparations with < 20% in the plasma volume by 2 h postinfusion. Whole body retention was prolonged for "'In versus 13 11 TI01 (T-of > 9d vs < 2d). Rapid dehalogenation was observed, with free 1311 excreted in the urine. No toxicity was observed. Modulation of antigen from circulating cells, skin and nodes was seen. The study shows the feasibility of imaging CTCL with "'1In TIOI and shows major differences in biodistribution when compared to 1311 TIOI.
Radioimmunoscintigraphy (PLANAR + SPECT) as a method in the follow-up of ovarian cancer patients
1Jst Department of Gynaecology and Obstetrics, 2Department of Nuclear Medicine, 3Ist Department of Surgery, University of Vienna, Austria; and 4Imperial Cancer Research Fund, London, UK More efficient methods are needed for screening after recurrent disease of ovarian cancer to improve the post-operative treatment and therefore the survival of these patients. Radioimmunoscintigraphy using monoclonal antibodies against a differentiation antigen (HMFG2) was performed in 25 patients, each of them having an ovarian tumour. The results were satisfactory, thus we decided to scan patients with ovarian cancer routinely as part of other investigations performed in the post-treatment follow-up of these patients. Each patient underwent a second look operation to assess if there was residual disease. Radioimmunoscintigraphy, including Single Photon Emission Computed Tomography (SPECT) was able to detect malignant lesions in some patients which could not be found by other non-invasive investigations. In these patients, the decision on further management was based upon the radioimmunoscintigraphy results. We conclude that radioimmunoscintigraphy, including SPECT, using an appropriate monoclonal antibody such as HMFG2, is able to improve the management of patients with ovarian cancer. patients with carcinoma of the bronchus suggesting a large quantity of the c-myc oncoprotein in these areas. Metastases derived from bronchial carcinoma did not take up the antibody. Ten patients with pulmonary metastases arising from sites other than lung also failed to take up Myc-l CT14. The cellular location of the c-myc oncoprotein is known to be nuclear and we conclude that detection in large primary tumours was due to cell death and subsequent release of the protein. Such antibodies may be of use in monitoring tumour load and response to therapy.
Antibody guided tumour detection using 131I labelled F(ab')2 fragments of an anti-CEA moab
1Istituto Oncologico Romagnolo and 2Servizio di Medicina Nucleare, Ospedale M. Bufalini, Cesena, Italy Twenty-eight patients with primary and/or metastatic gastro-intestinal cancer were studied by external scintigraphy after i.v. injection of 13li-labelled F(ab')2 fragments of a monoclonal antibody raised against carcinoembryonic antigen (FO23C5 -Sorin Biomedica). Primary tumours were seen in 11 out of 11 patients. Metastases were seen in 60-100% of cases depending on the different organs investigated.
Best images were obtained at 72, 96 and 120h. Lesions detected were confirmed either by conventional techniques such as X-ray, CT, ultrasound, or by surgical removal. Where possible the in vivo results were confirmed in vitro by immunoperoxidase staining of surgically removed tissues. As a negative control, patients having positive scans received an equal amount of a non-specific F(ab')2 fragment (225.28S). No positive scans were obtained in any cases. In order to improve tumour to background ratio, some of these patients were injected i.p. The results are encouraging. (GVHD) has been documented in many animal models. The original descriptions of GVHD showed that the graft versus host response (GVHR) was dependent on immunologically competent lymphocytes in the donor graft, a failure of host lymphocytes to reject the graft and the presence of a major histocompatibility difference between donor and recipient. The severity of the GVHR was proportional to the number of immunocompetent donor cells transferred and to the degree of histocompatibility difference. The GVHR probably involves lymphocytotoxicity directed against host lymphoreticular tissues. GVHD is a consequence of this but is not necessarily dependent on specific donor lymphocytotoxicity directed against the target organ. Host factors are important in the development of the disease. The further elucidation of the GVHR which showed that mature T-lymphocytes were responsible for the reaction and the suspicion that immune reconstitution could occur after bone marrow transplantation from lymphocyte precursors in the donor marrow which would not provoke the GVHR has led to many attempts to remove mature T-lymphocytes from the donor marrow before infusion. The urgency of the attempts to reduce GVHD arose out of the observation that acute GVHD and its complications was the major cause of death related directly to bone marrow transplantation and was the complication which limited the use of transplantation to matched sibling donors. The use of monoclonal antibodies (MAbs) for in vivo therapeutic approaches depends largely on their specificity. During the characterisation of ricin A chain-murine MAb conjugates, we found that the binding specificity of a MAb raised against human ovarian carcinoma (MOv2) seemed altered, whereas its cytotoxic specificity remained unchanged. Therefore, the binding reactivity of unmodified MOv2, conjugate intermediate MOv2-PDP and MOv2-A chain, was tested on 10 different histological types of human tumour cell lines. These three reagents bound with the two reference cell lines were tested (the ovary carcinoma SW626 and the colon carcinoma HT-29). The MOv2-PDP and MOv2-A chain also reacted with 2 cell lines which were unreactive with the unmodified MOv2 (the melanoma MALME 3M and the breast carcinoma MCF-7).
To elucidate the significance of these findings, the following experiments were performed: cross inhibitions between the unmodified and modified MAbs; comparative absorption tests with relevant and apparently irrelevant cell lines; biochemical analysis of the target antigens. The results suggest that after chemical modification the MAb MOv2 increases its binding activity, so that even low numbers of antigenic sites which may be present on apparently irrelevant cell lines can be detected. T cells were collected from peripheral blood, spleen and lymph nodes of normal healthy BALB/c donors by depleting IgG-pos cells after FicollHypaque flotation (Bilzer et al., 1982, Anticancer Res., 2, 345) . T cell-antibody binding was confirmed by micro-ELISA prior to application.
Five million T cells franked with hybridoma ascites were transferred on days 2, 4 6 and 12 after tumour implantation. The mean tumour mass determined in day 28 was 5.9 g, whereas mice treated with the antibody alone revealed 14.3 g on average. Untreated mice as well as mice treated with normal T cells had to be killed between days 14 and 21 because of tumour size and perforation.
Results of T-cel depletion with CAMPATH-1 in bone marrow transplantation (BMT) for chronic granulocytic leukaemia (CGL)
'Department of Haematology, Royal Postgraduate Medical School, London, and 2Department of Pathology, University of Cambridge, UK We have transplanted 27 patients with CGL using a rat monoclonal antibody, CAMPATH-1, for T-cell depletion. The patients can be divided into 'good risk' (16 patients in chronic phase (CP)) and 'poor risk' (two in second CP, three in acceleration, two in blast crisis, one with busulphan induced aplasia and three in CP from mismatched family donors). Conditioning consisted of daunorubicin 60 mg m 2, cyclophosphamide 120 mg kg-1 and TBI of [10] [11] [12] Gy in divided doses. Cyclosporine was given post-BMT to 21 of 27 patients. Donor marrow was treated with CAMPATH-1 ex vivo, and donor serum was used as the source of complement. The mean cell dose given was 2.7 x 108 kg-1 (range 1.3-4.3) of the 'good risk' group. All are alive with Karnofsky scores of 80-100% at 21-418 days. Engraftment was satisfactory with the average number of days to a neutrophil counts >0.5 x 1091-1 being 21 (range 11-33). Acute GVHD (Grade I-II) has occurred in only four patients to date, and chronic GVHD in four of the 11 evaluable patients. Of the 'bad risk', four are alive at 109-365 days. Three died of graft failure, 2 of idiopathic interstitial pneumonitis and 2 of CMV pneumonitis. Acute GVHD (Grade II-IV) occurred in 5 patients and chronic GVHD in 2 of the 4 patients surviving beyond 100 days. Graft failure was seen in five patients and, despite further conditioning and a second BMT without T-cell depletion for these patients, satisfactory engraftment has not been achieved in any case to date. We conclude that: (1) T-cell depletion successfully reduces the incidence and severity of GVHD, but (2) the incidence of graft failure in 'poor risk' patients is high, and the chances of achieving successful engraftment with a second BMT are low. A total of 32 immunotoxins (ITs) have been prepared coupling ricin A-chain with monoclonal antibodies reacting with several differentiation antigens expressed in the cell membrance of various malignant lymphoid cells. Twenty-two anti-T, nine anti-B, and one anti-HAL-DR ITs were evaluated using a protein synthesis inhibition assay. Measuring 14C-leucine incorporation, the Ligand Enhanced Specific Activity (LESA) factor (Casellas, P. et al., 1982, Int. J. Cancer, 30, 437) has been estimated for each IT. This study showed that the specific activity of ITs can differ from one class of antigen to another, LESA factor varying from 10 to 106 in the presence of activators (NH4Cl or monensin). Among anti-T ITs, CD5 and CD7 anti-T ITs were found to be the most active (LESA factor varying from 102 to 106) while four CD8 and two CD3 anti-T ITs did not show any activity.
Anti-CALLA ITs had poor efficiency. Only two out of nine anti-B ITs showed a certain level of killing efficacy (LESA factor > 103). Furthermore, this study showed that the LESA factor can differ within the same cluster of differentiation up to 4 log amplitude. Finally, this study suggests the influence of both antigens and antibodies on the cell-killing efficacy of ITs. Conjugates of abrin and ricin with 2 antimelanoma antibodies, 9.2.27 and anti-p2lo, were purified as described by Thorpe et al., Eur. J. Biochem., 1984, 140, 63) . The abrin immunotoxins were far more specific than the ricin conjugates, which were highly toxic also to a number of non-melanoma tumour lines. The 8 melanoma cell lines studied were 20 to 500 times more sensitive to the abrin than, to the corresponding ricin conjugates. The melanoma lines differed over a 250-fold range in their sensitivity to the abrin conjugates. The differences could not be accounted for by different levels of antigen expression, which varied over a 12-fold range, but largely reflected the associated differences, over a 4,000-fold range, in the sensitivity of cells to the native toxins.
Comparisons al., 1982 al., , Lancet, 60, 1266 Muirhead et al., 1983, Blood, 62, 327; Treleaven et al., 1984, Lancet, i, 70) . The success of such procedures will depend critically on the specificity and reactivity of the antibodies used. Here we report on the removal of B-lymphoma cells from human bone marrow using an improved generation of monodisperse magnetic polymer particles prepared by Ugelstad et al. and 3 B-Cell specific monoclonal antibodies prepared in this laboratory. The antibodies (ABI, AB2 and HH2) were of the IgM type and were either physically adsorbed or chemically bound to the particles. Four different Burkitt lymphoma cell lines (Rael, Raji, Bjab and Balm-1) were used. The tumour cells were mixed 1:1 with human bone marrow and a 25-fold excess of the charged particles and incubated in RPMI medium at 4°C with frequent turning. After 30min the magnetic beads were removed by placing the tissue bottles for 1 min on flat cobalt-samarium magnets. The number of remaining tumour cells in the supernatant was determined in a soft agar assay. It was found that the procedure was capable of depleting the tumour cells by up to 5 logs, without serious effect on the marrow progenitor cells, as measured in GM and GEMM assays. In order to prepare active anti-cancer drugantibody conjugates a number of basic requirements must be met. The candidate antibody must react selectively with tumour cells and localise to tumour tissue in vivo, and must withstand chemical substitution. The drug should be active against the target cells, and its structure must include chemically reactive sites distinct from functional sites in order to allow attachment without loss of anti-tumour activity. With these requirements fulfilled, there is a limit to the number of drug molecules which can be attached directly to the antibody molecule without irreversibly destroying its ability to bind to antigen but the molar ratio of drug: antibody may be substantially increased by the use of a highly substituted carrier molecule instead of drug alone.
Using the above criteria, conjugates of an anti-human osteosarcoma monoclonal antibody (791T/36) have been prepared with the cytotoxic drugs vindesine, daunomycin and methotrexate, the latter including drug-carrier-antibody conjugates. These conjugates were cytotoxic in vitro for tumour target cells which express the 791T/36-defined antigen, but were relatively non-toxic to nonantigenic cells. In vivo, radio-labelled conjugates localised to tumour xenografts in immune-deprived mice, and certain conjugates had a significant tumour-suppressive effect at doses containing therapeutic levels of drug. The main advantage of the conjugates was lack of toxicity to the murine hosts at levels greatly exceeding the LD50 of free drug. Drug-antibody conjugates appear to hold promise for future clinical application. Fifteen patients with ovarian cancer were treated intraperitoneally with 131I-radiolabelled antibodies HMFG1, HMFG2, AUA1, H17E2 given singly or as a mixture. Toxicity (reversible diarrhoea, leucopenia and thrombocytopenia) was noted at higher than 100 mCi activities. Most patients benefited symptomatically and, furthermore, in 6 out of 9 patients with stage III and minimal residual disease, a complete remission was achieved and maintained for 3-18 months after treatment.
Antibodies were introduced intracavitary for the treatment of malignant pleural effusions (20-100 mCi 1311). There has been resolution with no evidence of recurrence in 6 out of 7 pleural and 3 out of 3 pericardial effucions. Two patients with Grade IV glioma of brain unresponsive to other therapies were treated by arterial infusions of radiolabelled antibodies (A9, EGFR1) 45-102mCi 1311). A sustained clinical improvement was noted.
In conclusion, regionally administered radiolabelled antibodies (A9, EGFR1) (45-102mCi 131I anti-goat) was given in 2.5-5 times the amount of the first antibody 24 h later and the kinetics of the clearance showed that the administration of the second antibody was associated with a rapid increase in the removal of antibody from the circulation and the body. In one patient the circulating level of 1311 labelled antibody fell from 40% of its initial value to 8% within 3 h of the administration of the second antibody. By 60 h <10% of the radioactivity remained in the body.
The tumour was localised using a gamma camera and the radioactivity in a biopsy specimen of the tumour was four times as great as the radioactivity in the blood.
Therapeutic doses of radiolabelled antibodies given to patients have been well tolerated. The rapid clearance of radioactivity from the body using the second antibody may allow higher doses of radioactivity to be used safely and further studies are now justified. (Sunderland et al., 1984, Cancer Res., 44, 4496) .
To assess the usefulness of this potential tumour marker, NDOG2 has been used as the basis of two serum assays. Assay I measures PLAP activity whereas Assay 2 measures the NDOG determinant.
There was a close correlation between positive reactive staining with NDOG2 and pre-operative serum levels using both assays. Assay 1 proved to be of predictive value in 12 out of 44 patients studied and Assay 2 was of value, both in these cases and in a further 8 patients. In The expression of c-ras oncogene has been demonstrated in carcinoma of the colon and rectum. The activated cellular ras-oncogene synthesizes a protein (p21) with a point mutation at position 12. We developed monoclonal antibodies against amino acid sequences of p21 centred on this specific point mutation.
Using the peroxidase-anti-peroxidase techniques we stained sections from colorectal cancer using monoclonal antibodies to p21. Staining was positive in all tumour sections of 8 patients with colorectal malignancies and negative in both proximal and distal resection margins of colectomy specimens in these patients. Monoclonal antibody binding was found in both nucleus and inner side of the cell membrane.
Staining The c-myc oncogene has been implicated in the processes of normal cell proliferation and differentiation. Elevated levels of c-myc mRNA and its gene product (p62c-mYc), have been detected in a variety of solid tumours and cultured cell lines. Its precise role in normal cell function and in neoplastic transformation and progression has yet to be elucidated. We have used a monoclonal antibody, raised by peptide immunisation, to determine the distribution by immunoperoxidase staining of the c-myc oncogene product in archival specimens of colonic polyps and carcinomas. Samples from 42 patients with colon carcinoma, 24 with benign polyps and 15 normal colon biopsies were examined. Normal colon revealed maximum staining in the mid-zone of the crypts, corresponding to the zone of differentiation and maturation. The staining was predominantly cytoplasmic. Adenomatous polyps revealed the most intense pattern of staining in areas of dysplastic change. Colonic tumours showed a wide range of staining. Well differentiated tumours contained more cytoplasmic p62c-IYc than poorly differentiated tumours. These findings suggest that the c-myc oncogene product may play an important role in the evolution of colonic neoplasia. Pollet et al., 1985, Clin. Chem., 31, 41 . AP was quantified by a similar assay system including an AP specific monoclonal antibody (AP230). Tissue samples were obtained post mortem after donor nephrectomy, at pneumectomy or at the occasion of an induced abortion. The presence of Nagao-type PLAP was assessed by L-Leucine inhibition (1 mmol 1-1).
Adult lung tissue contained a mean PLAP activity of 78mUg-1 (range 3-181); this is 6.4% (range 1-22) of the total alkaline phosphatase activity. No L-Leucine sensitive PLAP activity could be found in these extracts. The main alkaline phosphatase found in adult lung tissue was tissue non-specific AP as could be demonstrated by the sensitivity to amino acids, L-p-bromotetramisole, neuraminidase treatment and heat inactivation analysis. Foetal lung tissue (n=5) between 11 and 15 weeks of gestation did not contain a substantial amount (>2Ukg-1) of PLAP. The biochemical results were confirmed by immunohistological localisation of PLAP on the respiratory bronchioli and alveoli, and by the histological localisation of AP in the tracheal and bronchial epithelium, the tracheal and bronchiolar glands, and the endothelium of small blood vessels. In a comparative study, human placental alkaline phosphatase (hPLAP), CA 125 and CEA were determined in sera of patients with ovarian (20) and non-ovarian tumours (45), and in patients with non-malignant disorders (126), using monoclonal antibodies against these antigens. The latter group consisted of 10 diabetic, 19 renal insufficiency, 50 chronic dialysis, 24 icteric non-cirrhotic, 9 icteric cirrhotic and 14 cirrhotic nonicteric patients. hPLAP and CA 125 had the same sensitivity (20%) for non-ovarian tumours, whereas that of CEA was 45%. In ovarian cancer, the sensitivity was 45% for hPLAP, 69% for CA 125 and only 10% for CEA. hPLAP had the lowest false-positivity (2%) in patients with non-malignant disorders (1 diabetic and 2 patients on chronic dialysis). In contrast, CA 125 and CEA were increased in 23% and 18%, respectively, of patients with benign pathologies. In this group, cirrhotic patients had the highest prevalence (88%) of elevated serum CA 125 levels. CA 125 was localised immunohistochemically in normal liver tissue of a patient with a metastatic poorly differentiated pancreatic adenocarcinoma having increased serum levels of hPLAP, CEA and CA 125. Positive CA 125 staining was observed intracellularly in hepatocytic lysosomes and was absent in Kuppfer cells. Normal liver does not contain detectable CA 125 staining. This observation is suggestive for uptake of CA 125 by the hepatocytic asialoglycoprotein carrier mechanism. This hypothesis also explains the elevated serum levels of CA 125 in patients with impaired liver function. The sensitivity of hPLAP in detecting ovarian cancer is slightly inferior to that of CA 125, but its specificity is much higher. The clinical value of CA 125 as a marker in advanced ovarian cancer during and after therapy was studied.
In 26 patients with seropapillary or anaplastic (FIGO histological group Ic or 5) ovarian cancer FIGO stage III and IV, serum samples were drawn and then frozen for later analyses before each chemotherapy cycle, before second look operations and at each visit during follow up. First sample was taken at different phases of disease. Analyses were carried out with kits from International CIS, France.
Fifteen of 26 patients (60%) showed positive marker (>35Uml-1) at any time. If patients clinically not expected to show high marker are excluded, 15/20 (75%) showed positive marker. There were definite patterns over time depicting tumour response during chemotherapy. There was a correlation between pre-operative marker value and findings during second look operations, although there could be widespread cancer with a normal marker value. In two cases relapsing during follow up there was a lead time of at least 6.8 and 1 month respectively between high marker value and clinically evident tumour.
It is concluded that CA 125 correlates well with evolution of disease in -80% of the cases; could perhaps be used as an early sign of sensitivity to cytostatic drugs; correlates with findings at second look, but cannot be used as a subsitute for operation, and can signal a relapse before it becomes clinically evident. Experiments carried out using patients' sera after both a diagnostic and therapeutic injection of monoclonal antibodies labelled with radioactive iodine show quite clearly the presence of human anti-mouse antibodies.
Screening of our patients' sera has been done by employing two methods: (1) a modified enzymelinked immunosorbent assay, ELISA, and (2) hybridoma targeting which employs the use of antibody bearing hybridoma cell cytospins.
Our studies show that the reponse is anti-mouse not anti-idiotypic and the response is greatest if the interval between the first and second injections is greater than 10 days, due to the mainly IgG secondary immune response, and negligible if patients are given the diagnostic and therapeutic injections within 7 days of each other, hence preventing the development of a large secondary immune response. Monoclonal antibody MC 211 (IgA class) was produced by hybridomas after immunisation of BALB-c mice with membrane-enriched fractions of human mammary carcinoma and breast cell line MCF7. Using an immunohistochemical method, with the avidin-biotin peroxidase complex, the reactivity of MC 211 MoAb was studied in formalin-fixed paraffin embedded sections of surgical specimens.
Twenty-five of the 27 mammary adenocarcinomas tested were strongly positive (50 to 80% positive cells); the 2 others were weakly positive (10% positive cells); one mammary endocrine carcinoma was negative;
non-breast adenocarcinomas were tested; digestive carcinomas were positive (7/7: colon, pancreas, stomach adenocarcinomas; 3/4 ovarian carcinomas were weakly positive; the two pulmonary adenocarcinomas tested were weakly positive;
The other tumours tested were negative: 3 endocrine tumours; 2 pleural mesotheliomas; 2 malignant melanomas; 3 sarcomas. Therefore, MC 211 monoclonal antibody seems to be of interest in the diagnosis of adenocarcinomas and will be further evaluated in immunohistochemistry for the detection of bone marrow micrometastases from breast carcinomas at the time of surgery and as radioimmunoimaging agent for the diagnosis of lymph node involvement and other metastases.
Monoclonal antibodies to liver F-antigen discriminate between parenchymal and ductular epithelial cells in adult human hepatic tissue P.J. Higgins
Memorial Sloan-Kettering Cancer Center, New York, USA Hybridoma cell lines producing monoclonal antibodies (MAbs) to F-antigen of liver were prepared by fusion of NS-1 myeloma cells with spleen cells obtained from CBA mice immunised with saline extracts of BALB/c mouse liver. MAbs reactive with F-antigen were selected by comparative immuno-blot screening using electrophoretically separated proteins from BALB/c liver and polyclonal anti-F-antigen sera. Immunohistochemical staining of paraffin-embedded and cleared sections of normal adult human liver with two such MAbs (I/2, I/5) defined epitopes of Fantigen expressed only on lobular parenchymal hepatocytes; bile duct epithelium, sinusoidal lining cells, endothelial tissue and portal tract mesenchymal elements were unreactive with these MAbs. In a screen of 50 different malignant and benign hepatic neoplasms of both murine and human origin, MAbs 1/2 and 1/5 clearly discriminated hepatocellular from ductular carcinomas and adenomatous foci from bile duct hyperplasia. It appeared that protease pre-treatment of liver sections was necessary for maximum immunocytochemical resolution of F-antigen with 1/2 and 1/5. Work is currently in progress to define, using the current panel of MAbs, the controversial origin of the 'oval' epithelial cell induced in the livers of carcinogen-treated animals.
Monoclonal antibodies to prostatic specific antigens
In order to understand better the mechanism involved in normal and abnormal prostatic growth, we attempted to assess human specific antigens defined by monoclonal antibodies. Balb/c mice were immunised with membrane antigens hyperplasia (BPH) and with protein from rat ventral prostate cytosol that binds estramustine. This antigen was obtained from Leo Research Laboratories and was purified to homogeneity using chromatography on DEAE-cellulose, Sephadex G-100, Octyl-Sepharose CL-4B and polyacrylamide gel electrophoresis. The screening method for the hybridoma supernatants used immunoperoxidase stained frozen sections of human tissues as well as the dot blotting method. The antigens found by this method are of 3 classes: a specific secretion product of the prostate which is polyepithelial and stroma specific. The molecular analysis was defined by 3 5S-methionine labelling experiments of cultured prostatic cells and subsequent SDS PAGE after immunoprecipitation of supernatant by the selected hybridoma antibodies. Except for the estramustine binding protein, the functions of the antigens are still unknown and are under investigation. They may be of value in understanding the physiology of normal prostate, benign hyperplasia and cancer. The antibody 9.2.27 directed against the 250 K melanoma-associated antigen (Morgan et al., 1981, Hybridoma, 1, 27) has been extensively studied. Although the antigen is present on some skin cells (Ross et al., 1984, Cancer Res., 44, 4642) , it has not been identified on other tumour types and has been considered specific for melanomas. More than 90% of human melanomas express the antigen (Oldham et al., 1984, J. Clin. Oncol., 2, 1235), and recently the application of the 9.2.27 antibody to the diagnosis and therapy of melanomas has been intensively explored.
During a study of antisarcoma antibodies the accidental observation was made that the 9.2.27 antibody binds strongly to sarcoma cells. Binding to single cell suspensions was demonstrated by indirect immunofluorescence and by radioactivity measurements using labelled antibody, and binding to cryostat sections was shown by peroxidase staining. In vivo binding of radiolabelled antibody to -sarcomas was demonstrated in tumour bearing athymic mice as well as in patients with metastaic sarcoma. Binding of 9.2.27 also occurs to proliferating fibroblasts in primary cultures. Immunoprecipitation studies demonstrated that the antigen on fibroblasts and sarcoma cells is identical to that present on melanoma cells. The sarcomas represent a heterogeneous group of tumours with multiple subtypes that are difficult to characterise in detail. Recently, we have succeeded in preparing a monoclonal antibody which is highly specific for human sarcomas. Cells from a xenografted human osteosarcoma were used for immunisation and antibody-secreting hybridomas were screened by indirect fluorescence using unfixed cells. Fibroblasts from several sarcoma patients were used as negative controls. The new antibody, TP-1 (isotype Ig2a), recognises a trypsin-resistant protein of MW 105,000. When tested on acetonefixed cryostat sections, using a 3-step peroxidase method, the antibody showed no significant binding to a wide range of normal adult tissues, but bound weakly to foetal kidney tubules. Forty-one nonsarcoma malignancies of different histological types were negative. In 29 sarcomas tested, positive staining was obtained in 6/6 osteosarcomas, 5/5 malignant fibrous histiocytomas, 1/1 chondrosarcoma, 2/2 synovial sarcomas, 2/2 malignant hemangiopericytomas and 3/5 unclassified sarcomas. Three rhabdomyo-, 2 leiomyo-and 3 lipo-sarcomas were negative. The specificity profile renders TP-1 a potentially useful reagent in the histological identification and subclassification of sarcomas. Using a radiolabelled F(ab')2 fragment we have successfully imaged a human sarcoma growing s.c. in nude mice.
Rat monoclonal antibodies to human uveal melanomas
Departments of 1Biochemistry and 2Ophthalmology, University of Glasgow, UK Previous investigations into the immunology of uveal melanomas have been limited by the lack of well defined antigens.
Rat monoclonal antibodies to uveal melanomas have been produced using fresh unfixed tissue. A panel of these antibodies is being used to determine the antigenic profiles of a bank of human uveal melanomas by means of ELISA. Considerable heterogeneity amongst primary tumours has been revealed.
The antigenic profile of each tumour is being correlated with the tumour cell type and patient survival. It is envisaged that these studies will enable clinically significant antigens to be identified. HMFG1 and HMFG2 (Taylor-Papadimitriou, et al., 1981, Int. J. Cancer, 28, 17) raised against milk fat globule membranes react with a broad spectrum of epithelial neoplasms and are considered as epithelium specific, tumourassociated antibodies.
Approximately 5 gm formalin-fixed tissue sections from 38 primary lung cancers (7 squamous, 5 adenocarcinomas, 4 large cell undifferentiated and 22 small cell carcinomas) ranging from well to poorly differentiated types, were stained with HMFG1 and HMFG2 mabs, using an indirect, two-step immunoperoxidase method.
It has been shown that all the non-small-cell cancers (NSCC) react strongly with the above mabs, regardless of their degree of differentiation. It is concluded, therfore, that these mabs could be a useful tumour marker of NSCC.
On the other hand, the negative reaction of SCC with these mabs could be related to the specific origin of these tumours. To improve the specificity and efficiency of chemotherapeutic agents, three different drugs (Adriamycin -Ad; Methotrexate -MTX; and Chlorambucil -CBL) were covalently coupled to monoclonal antibodies with specificity for cell surface antigens. The coupling procedures were carefully monitored, and optimised for maximum recovery of protein, antibody and drug activity. The results fell into three different groups: (a) Adriamycin coupled (with difficulty) by the iodacetyl derivative produced conjugates with 8-10 Ad molecules per antibody molecule. On testing in vitro and in vivo the conjugates were highly specific and active, but considerably less toxic than free adriamycin (although more specific); (b) MTX, activated by N-hydroxysuccinimide, led to conjugates containing 13-15mol of MTX per antibody molecule. Again, these were highly specific and acted both in vitro and in vivo; (c) CBL coupled using the same method as for MTX, led to 35 residues of CBL per monoclonal antibody molecule, with good retention of both drug and antibody activity. The CBL conjugates were, again, highly specific, but in addition were at least 6 times more toxic than free CBL. This is one of the first examples where antibody-drug conjugates are more active than free drug -and this conjugate could eradicate tumour cells grown in ascites form in mice. Thus carefull attention to drug coupling procedures to give high drug/antibody ratios can lead to production of toxic and specific agents for targeting. Immunoreactivity of labelled antibody (HMFG2) has been tested by ELISA after prolonged exposure (3 h) to NBS without any observable loss of antigen binding.
The achievement of such labelling efficiencies may eliminate the need for subsequent purification procedures. This will be particularly useful in high activity iodinations for antibody-guided radiotherapy. In a separate set of experiments, '25I-labelled F(ab')2 fragments of AUA1 when compared with whole AUAI produced better tumour to normal organ ratios due to the rapid blood clearance of the fragments.
F(ab')2 fragments of monoclonal antibodies offer significant promise for tumour imaging and possible therapy. (Hi 7E2) against placental type alkaline phosphatase (PLAP) and testicular placental-like alkaline phosphatase was used in a prospective study of radioimmunoscintigraphy of 15 patients known or suspected to have germ cell carcinoma of testis or carcinoma of ovary or cervix. Good quality images of neoplastic lesions were obtained in the majority of patients with active disease. In two patients with normal conventional radiology, antibody guided imaging located the site of microscopic disease, thus aiding surgical lymphadenectomy. No false positive localisation was seen in patients with PLAPnegative tumours or sites of inflammation such as lung abscess.
This method appears to be a potentially important new adjunct in the diagnosis, staging and monitoring of disease status in patients with PLAPpositive neoplasms such as testicular, ovarian and cervical cancer. Although technetium-99m has ideal physical properties for imaging, little use has been made of the radionuclide for labelling monoclonal antibodies -presumably because of labelling difficulties. However, recently a new method for preparing 99mTc radiopharmaceuticals based on substitution reactions of 991TcNCI4 has been described. This agent can be prepared in the dry form without the presence of any contaminating metal ions and leads to the formations of Tc chelates in the presence of a Tc nitrido group. Taking advantage of the unique properties of this compound, we decribe a simple method of labelling Mg quantities of monoclonal antibodies for evaluation of the clinical usefulness of 99mTcN-Mab complexes as diagnostic reagents.
The stability and activity of these complexes were examined in vitro with a simple binding assay wich involved antigen positive and antigen negative cells. The complexes were shown to be highly specific and would bind antigen positive cells 10 times greater than antigen negative cells.
In an in vivo experimental model (BL6 x BALB/c)Fl mice carrying palpable ITT(l) 75NS tumours (0.4-1.5cm diameter) were injected i.v. via tail vein with either of two monoclonal antibodies labelled with 99mTcNCl4. Mice were either scanned with a gamma camera or their tissues were removed and the localisation of radiolabelled antibody calculated as cpm g-1 of organ, results were calculated as a ratio of the tissue to blood distribution. The studies showed that specific localisation had occurred. Tumours (4mm) could be successfully imaged without the need for background subtraction. 
